Jesse Gelsinger died in a gene therapy trial — the FDA shut down the entire field

Jesse Gelsinger was an 18-year-old from Arizona with ornithine transcarbamylase (OTC) deficiency, a rare liver disease that prevents the body from breaking down ammonia. He enrolled in a gene therapy trial at the University of Pennsylvania in September 1999. The trial used an adenoviral vector to deliver a corrected gene. Gelsinger had elevated ammonia levels at enrollment — a known exclusion criterion — but was included anyway as a substitute for a dropout. The pressure to fill the trial slot overrode the protocol.

Four days after the injection, Gelsinger suffered a massive immune response. His body attacked the adenoviral vector with a cytokine storm, leading to multiple organ failure and brain death. He died on September 17, 1999. The FDA immediately halted all gene therapy trials in the United States — the first such shutdown in history. An investigation found that the University of Pennsylvania had violated multiple research protocols, including failing to report serious adverse events in previous patients.

The consequences reshaped medical research. The FDA imposed stricter oversight on gene therapy trials, including mandatory adverse event reporting and independent safety monitoring. The University of Pennsylvania and Children's National Medical Center each paid over $500,000 in settlements. James Wilson, the lead investigator, was banned from human trials for five years. Gene therapy research was set back by years. The case became a defining example of how the pressure to produce breakthrough results in medical research can override patient safety.